贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床疗效
|
摘要
目的:探究慢性心力衰竭(CHF)行贝那普利联合阿托伐他汀治疗对患者心率、血浆脑钠肽N末端前体(NT-proBNP)及神经内分泌因子昼夜节律的影响。方法:选取2016年9月—2017年9月我院收治的102例CHF患者,按照随机数字表法分为两组,各51例。对照组给予贝那普利(10 mg,qd)治疗,研究组于此基础上加以阿托伐他汀(10 mg,qd)治疗,比较两组昼夜心率比、NT-proBNP水平以及神经内分泌因子昼夜节律情况。结果:研究组昼、夜心率及夜昼比值显著高于对照组,差异有统计学意义(P <0.05);两组治疗后NT-proBNP水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P <0.05);两组治疗后血管紧张素Ⅱ(AngⅡ)、去甲肾上腺素(NE)、醛固酮(ALD)中位数及振幅均优于治疗前,且研究组优于对照组,差异有统计学意义(P <0.05)。结论:贝那普利及阿托伐他汀联合治疗CHF可有效改善患者心率及NT-proBNP水平,且有助于神经内分泌因子昼夜节律改善。
Objective: To investigate the effect of benazepril combined with atorvastatin on the circadian rhythm of heart rate, plasma brain natriuretic peptide N-terminal precursor(NT-proBNP) and neuroendocrine factors in patients with chronic heart failure(CHF). Methods: 102 patients with CHF admitted to our hospital from September 2016 to September 2017 were selected and randomly divided into two groups, 51 cases each. The patients in the control group were treated with benazepril(10 mg, qd), and the patients in the study group were treated with atorvastatin(10 mg, qd). The daytime and nighttime heart rate ratio and the circadian rhythm of NT-proBNP level and neuroendocrine factor were compared between the two groups. Results: The daytime and nighttime heart rate and daytime-to-daytime ratio in the study group were signi?cantly higher than those in the control group, and the differences were statistically signi?cant(P<0.05). The level of NT-proBNP in the two groups after treatment was lower than that before treatment, and the level in the study group was lower than that in the control group, with statistically signi?cant differences(P<0.05). The median and amplitude of angiotensin Ⅱ(Ang Ⅱ), norepinephrine(NE) and aldosterone(ALD) in the two groups after treatment were better than those before treatment, and the median and amplitude in the study group were better than those in the control group, with statistically signi?cant differences(P<0.05). Conclusion: Benazepril combined with atorvastatin can effectively improve the heart rate and NT-proBNP level of the patients in the treatment of CHF and contribute to the improvement of the circadian rhythm of neuroendocrine factors.
Objective: To investigate the effect of benazepril combined with atorvastatin on the circadian rhythm of heart rate, plasma brain natriuretic peptide N-terminal precursor(NT-proBNP) and neuroendocrine factors in patients with chronic heart failure(CHF). Methods: 102 patients with CHF admitted to our hospital from September 2016 to September 2017 were selected and randomly divided into two groups, 51 cases each. The patients in the control group were treated with benazepril(10 mg, qd), and the patients in the study group were treated with atorvastatin(10 mg, qd). The daytime and nighttime heart rate ratio and the circadian rhythm of NT-proBNP level and neuroendocrine factor were compared between the two groups. Results: The daytime and nighttime heart rate and daytime-to-daytime ratio in the study group were signi?cantly higher than those in the control group, and the differences were statistically signi?cant(P<0.05). The level of NT-proBNP in the two groups after treatment was lower than that before treatment, and the level in the study group was lower than that in the control group, with statistically signi?cant differences(P<0.05). The median and amplitude of angiotensin Ⅱ(Ang Ⅱ), norepinephrine(NE) and aldosterone(ALD) in the two groups after treatment were better than those before treatment, and the median and amplitude in the study group were better than those in the control group, with statistically signi?cant differences(P<0.05). Conclusion: Benazepril combined with atorvastatin can effectively improve the heart rate and NT-proBNP level of the patients in the treatment of CHF and contribute to the improvement of the circadian rhythm of neuroendocrine factors.
引文
[1]沈红枫,夏海江.左卡尼汀注射液联合阿托伐他汀钙片治疗慢性心力衰竭的临床研究[J].中国临床药理学杂志,2017,33(5):395-397,407.
[2]陈素琴,黎明江,吴限.贝那普利联合螺内酯治疗慢性心力衰竭疗效和安全性的Meta分析[J].中国心血管病研究,2017,15(8):739-743.
[3]彭环庆,彭志允,范志勇,等.阿托伐他汀对不同血脂水平的慢性心力衰竭患者血管内皮功能的影响[J].中国老年学杂志,2015,35(19):5486-5487.
[4]侯宇鹏,慕春言,苏毅,等.不同剂量阿托伐他汀治疗冠心病慢性心力衰竭的临床疗效对比探讨[J].临床研究,2016,24(11):79-80.
[5]倪伟.曲美他嗪联合阿托伐他汀钙治疗慢性心力衰竭的临床疗效[J].心血管康复医学杂志,2016,25(6):607-609.
[6]方玲,李冠兰,李云,等.贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床疗效[J].现代生物医学进展,2017,17(11):2102-2105.
[7]崔艳红,马翠芳.不同剂量阿托伐他汀治疗冠心病慢性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2015,23(1):59-61.
[8]张晋.阿托伐他汀治疗冠心病并慢性心力衰竭患者疗效观察[J].数理医药学杂志,2018,31(12):1837-1839.
[9]李梅.阿托伐他汀对改善慢性心力衰竭患者心肌纤维化的效果观察[J].中国社区医师,2018,34(29):31,33.
[10]钟冬梅,胡英,王苓,等.贝那普利对慢性心力衰竭患者疗效及血浆脑钠素、高敏C反应蛋白水平的临床价值[J].中国医药科学,2015,5(18):125-128.
[11]严晓伟,许顶立,黄峻,等.中国慢性心力衰竭患者应用贝那普利的有效性和安全性荟萃分析[J].中华医学杂志,2014,94(37):2907-2913.
[2]陈素琴,黎明江,吴限.贝那普利联合螺内酯治疗慢性心力衰竭疗效和安全性的Meta分析[J].中国心血管病研究,2017,15(8):739-743.
[3]彭环庆,彭志允,范志勇,等.阿托伐他汀对不同血脂水平的慢性心力衰竭患者血管内皮功能的影响[J].中国老年学杂志,2015,35(19):5486-5487.
[4]侯宇鹏,慕春言,苏毅,等.不同剂量阿托伐他汀治疗冠心病慢性心力衰竭的临床疗效对比探讨[J].临床研究,2016,24(11):79-80.
[5]倪伟.曲美他嗪联合阿托伐他汀钙治疗慢性心力衰竭的临床疗效[J].心血管康复医学杂志,2016,25(6):607-609.
[6]方玲,李冠兰,李云,等.贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床疗效[J].现代生物医学进展,2017,17(11):2102-2105.
[7]崔艳红,马翠芳.不同剂量阿托伐他汀治疗冠心病慢性心力衰竭的疗效观察[J].实用心脑肺血管病杂志,2015,23(1):59-61.
[8]张晋.阿托伐他汀治疗冠心病并慢性心力衰竭患者疗效观察[J].数理医药学杂志,2018,31(12):1837-1839.
[9]李梅.阿托伐他汀对改善慢性心力衰竭患者心肌纤维化的效果观察[J].中国社区医师,2018,34(29):31,33.
[10]钟冬梅,胡英,王苓,等.贝那普利对慢性心力衰竭患者疗效及血浆脑钠素、高敏C反应蛋白水平的临床价值[J].中国医药科学,2015,5(18):125-128.
[11]严晓伟,许顶立,黄峻,等.中国慢性心力衰竭患者应用贝那普利的有效性和安全性荟萃分析[J].中华医学杂志,2014,94(37):2907-2913.